Device training (in-home or virtual) by an experienced nurse
Assist with understanding the insurance process
Arrange for the first NGENLA shipment from the pharmacy and address issues that may lead to pharmacy delays or treatment interruptions
Provide eligible, commercially insured patients with copay program enrollment
The program includes a Patient Care Consultant (PCC). They will work directly with your doctor, insurance, and pharmacy to help your child get started on NGENLA as soon as possible.
Once you and your child's doctor determine that NGENLA is the right treatment, the doctor will prescribe the therapy.
You and your child's doctor will then complete the Pfizer Bridge Program Enrollment Form. A PCC, who is part of the Pfizer Bridge Program, will contact you following your enrollment. Watch for a call from 1-800-645-1280.
Your child's doctor or the PCC will contact your insurance plan to confirm the growth hormone products available to your child and review the information with you.
Prescription drug plans (“plan”) often require your child's doctor to get approval or prior authorization before your child can be treated with NGENLA.
Your plan will review the information submitted by your child's doctor and either approve or deny your child's prescription. Your child's doctor or the PCC will contact you with the plan’s decision. If your child's prescription is denied, the Pfizer Bridge Program can provide information on appeals requirements.
A specialty pharmacy will send NGENLA directly to your home. Your PCC can share the specialty pharmacy information with you, assist with coordinating medication shipments, and help with any medication or device issues that may arise.
The Pfizer Bridge Program can help arrange in-home or virtual device training by an experienced nurse. View demonstration videos here. You can also contact the device support hotline at 1-800-645-1280 to speak with an experienced professional.
Plans may require your child to be reapproved to continue growth hormone treatment. Your PCC will contact you to ensure there is no lapse in your child's NGENLA treatment.
Be sure to attend all scheduled doctor's appointments to prevent any delays in reauthorization.
This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.
© 2023 Pfizer Inc. All rights reserved. PP-SMT-USA-0115
View mobile Terms and Conditions at engagedrx.com/pghd. Msg & Data rates may apply. Msg frequency varies. Text HELP for info, STOP to opt out. Pfizer’s Privacy Policy can be found at pfizer.com/privacy.
This confirms that you will soon be receiving weekly dosing reminders for NGENLA.
Growth hormone should not be used in children after the growth plates have closed.
Growth hormone should not be used in children with some types of eye problems caused by diabetes (diabetic retinopathy).
Growth hormone should not be used in children who have cancer or other tumors.
Growth hormone should not be used in children who are critically ill because of some types of heart or stomach surgery, trauma, or breathing (respiratory) problems.
Growth hormone should not be used in children with Prader-Willi syndrome who are very overweight or have breathing problems including sleep apnea.
NGENLA should not be used by children who have had an allergic reaction to somatrogon-ghla or any of the ingredients in NGENLA. Look for prompt medical attention in case of an allergic reaction.
Some children have developed diabetes mellitus while taking growth hormone. Dosages of diabetes medicines may need to be adjusted during treatment with NGENLA. Children should be watched carefully if NGENLA is given along with glucocorticoid therapy and/or other drugs that are processed by the body in the same way.
In childhood cancer survivors, treatment with growth hormone may raise the likelihood of a new tumor, particularly some benign (non-cancerous) brain tumors. This likelihood may be higher in children who were treated with radiation to the brain or head. Your child’s health care provider will need to check your child for a return of cancer or a tumor.
Children treated with growth hormone have had increased pressure in the brain. If your child has headaches, eye problems, nausea (feeling like you are going to be sick), or vomiting, contact your child’s health care provider.
NGENLA may decrease thyroid hormone levels. Decreased thyroid hormone levels may change how well NGENLA works. Your child’s health care provider will do blood tests to check your child’s hormone levels.
Children treated with growth hormone should be checked regularly for low serum cortisol levels and/or the need to increase the dose of the glucocorticoids they are taking.
In children experiencing fast growth, curvature of the spine may develop or worsen. This is also called scoliosis. Children with scoliosis should be checked regularly to make sure their scoliosis does not get worse during their growth hormone therapy.
Use a different area on the body for each injection. This can help to avoid skin problems such as lumpiness or soreness.
Growth hormone treatment may cause serious and constant stomach (abdominal) pain. This could be a sign of pancreatitis. Tell your child’s health care provider if your child has any new stomach (abdominal) pain.
In studies of NGENLA in children with GHD, side effects included injection site reactions such as pain, swelling, rash, itching, or bleeding. Other side effects were the common cold, headache, fever (high temperature), low red blood cells (anemia), cough, vomiting, decreased thyroid hormone levels, stomach pain, rash, or throat pain.
A health care provider will help you with the first injection. He or she will also train you on how to inject NGENLA.
Rx only
NGENLA is a prescription product for the treatment of growth failure in children 3 years of age and older who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).